Clinical Data’s Cogenics Division to Provide Global Genotyping Solutions for Lundbeck’s Clinical Studies

Clinical Data, Inc. has announced that its Cogenics® division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis.

Lundbeck is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.

Under the agreement, Cogenics will employ its clinical genotyping platforms and expertise based in Morrisville, North Carolina and Bernried, Germany, to support Lundbeck’s clinical studies world-wide, initially focusing on Lundbeck’s Phase I studies. The term of the agreement is open-ended and the parties intend to collaborate on multiple projects going forward.

“This agreement with Lundbeck underscores Cogenics’ leading position in the clinical genotyping field, and we are very pleased to form this partnership,” says Michael Lutz, Global General Manager of Cogenics.

“Having conducted more than 1700 genotyping studies to support clinical drug development, we are well positioned to provide value-added genotyping solutions to Lundbeck on a global basis and in a consistent, high quality manner.”